Troy Hinkley

Troy Hinkley

Auto-generated profile, based on publicly available information

Troy Hinkley

HDT Bio

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2018 in The Analyst
Verified
Journal Article
Open access
PDF file
THT. C. Hinkley
T. C. Hinkley
SGS. Garing
S. Garing
SSS. Singh
S. Singh
ANA-L. M. Le Ny
A-L. M. Le Ny
KNK. P. Nichols
K. P. Nichols
SNSam Nugen
Sam Nugen
Rapid detection of bacteria responsible for foodborne diseases is a growing necessity for public health. Reporter bacteriophages (phages) are robust biorecognition elements uniquely suited for the rapid and sensitive detection of bacterial species. The advantages of phages include their host specificity, ability to distinguish viable and non-viable cells, low cost, and ease of genetic engineering. Upon infection with reporter phages, target bacteria express reporter enzymes encoded within the phage genome. In this study, the T7 coliphage was genetically engineered to express the newly developed luceriferase, NanoLuc (NLuc), as an indicator of bacterial contamination. While several genetic approaches were employed to optimize reporter enzyme expression, the novel achievement of this work was the successful fusion of the NanoLuc reporter to a carbohydrate binding module (CBM) with specificity to crystalline cellulose. This novel chimeric reporter (nluc::cbm) bestows the specific and irreversible immobilization of NanoLuc onto a low-cost, widely available crystalline cellulosic substrate. We have shown the possibility of detecting the immobilized fusion protein in a filter plate which resulted from a single CFU of E. coli. We then demonstrated that microcrystalline cellulose can be used to concentrate the fusion reporter from 100 mL water samples allowing a limit of detection of <10 CFU mL−1E. coli in 3 hours. Therefore, we conclude that our phage-based detection assay displays significant aptitude as a proof-of-concept drinking water diagnostic assay for the low-cost, rapid and sensitive detection of E. coli. Additional improvements in the capture efficiency of the phage-based fusion reporter should allow a limit of detection of <10 CFU per 100 mL.

13 December 2018 in The Analyst
Verified
Journal Article
Closed access
PDF file
Danhui WangDanhui Wang
Danhui Wang
THTroy Hinkley
Troy Hinkley
JCJuhong Chen
Juhong Chen
JTJoey Talbert
Joey Talbert
SNSam Nugen
Sam Nugen
The monitoring of drinking water for indicators of fecal contamination is crucial for ensuring a safe supply. In this study, a novel electrochemical method was developed for the rapid and sensitive detection of Escherichia coli (E. coli) in drinking water. This strategy is based on the use of engineered bacteriophages (phages) to separate and concentrate target E. coli when conjugated with magnetic beads, and to facilitate the detection by expressing gold binding peptides fused alkaline phosphatase (GBPs-ALP). The fusion protein GBPs-ALP has both the enzymatic activity and the ability to directly bind onto a gold surface. This binding-peptide mediated immobilization method provided a novel and simple approach to immobilize proteins on a solid surface, requiring no post-translational modifications. The concentration of E. coli was determined by measuring the activity of the ALP on gold electrodes electrochemically using linear sweep voltammetry (LSV). This approach was successfully applied in the detection of E. coli in drinking water. We were able to detect 105 CFU mL−1 of E. coli within 4 hours. After 9 hours of preincubation, 1 CFU of E. coli in 100 mL of drinking water was detected with a total assay time of 12 hours. This approach compares favorably to the current EPA method and has the potential to be applied to detect different bacteria in other food matrices.

28 January 2022 in Lab on a Chip
Verified
Journal Article
Open access
PDF file
LALuis F. Alonzo
Luis F. Alonzo
THTroy C. Hinkley
Troy C. Hinkley
AMAndrew Miller
Andrew Miller
RCRyan Calderon
Ryan Calderon
SGSpencer Garing
Spencer Garing
ANAnne-Laure M. Le Ny
Anne-Laure M. Le Ny
A phage-based microfluidic platform for highly sensitive and rapid detection of E. coli in low-resource settings.

25 October 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
SLShanna S. Leventhal
Shanna S. Leventhal
TBThomas Bisom
Thomas Bisom
DCDean Clift
Dean Clift
DRDeepashri Rao
Deepashri Rao
KMKimberly Meade-White
Kimberly Meade-White
David HawmanDavid Hawman
David Hawman
Crimean-Congo Hemorrhagic Fever Virus (CCHFV) is a negative-sense RNA virus spread by Hyalomma genus ticks across Europe, Asia, and Africa. CCHF disease begins as a non-specific febrile illness which may progress into a severe hemorrhagic disease with no widely approved or highly efficacious interventions currently available. Recently, we reported a self-replicating, alphavirus-based RNA vaccine that expresses the CCHFV nucleoprotein and is protective against lethal CCHFV disease in mice. This vaccine induces high titers of non-neutralizing anti-NP antibodies and we show here that protection does not require Fc-gamma receptors or complement. Instead, vaccinated mice deficient in the intracellular Fc-receptor TRIM21 were unable to control the infection despite mounting robust CCHFV-specific immunity. We also show that passive transfer of NP-immune sera confers significant TRIM21-dependent protection against lethal CCHFV challenge. Together our data identifies TRIM21-mediated mechanisms as the Fc effector function of protective antibodies against the CCHFV NP and provides mechanistic insight into how vaccines against the CCHFV NP confer protection.

1 March 2021 in Food and Bioproducts Processing
Verified
Journal Article
Closed access
ZWZhixin Wang
Zhixin Wang
JQJingjie Qi
Jingjie Qi
THTroy C. Hinkley
Troy C. Hinkley
SNSam R. Nugen
Sam R. Nugen
JGJulie Goddard
Julie Goddard

26 June 2024 in npj Vaccines
Verified
Journal Article
Open access
PDF file
KEKristina R. Edwards
Kristina R. Edwards
HMHarman Malhi
Harman Malhi
KSKarina Schmidt
Karina Schmidt
ADAmelia R. Davis
Amelia R. Davis
LHLeah J. Homad
Leah J. Homad
AMAndrew T. McGuire
Andrew T. McGuire
Epstein-Barr virus (EBV) is associated with several malignancies, neurodegenerative disorders and is the causative agent of infectious mononucleosis. A vaccine that prevents EBV-driven morbidity and mortality remains an unmet need. EBV is orally transmitted, infecting both B cells and epithelial cells. Several virally encoded proteins are involved in entry. The gH/gL glycoprotein complex is essential for infectivity irrespective of cell type, while gp42 is essential for infection of B cells. gp350 promotes viral attachment by binding to CD21 or CD35 and is the most abundant glycoprotein on the virion. gH/gL, gp42 and gp350, are known targets of neutralizing antibodies and therefore relevant immunogens for vaccine development. Here, we developed and optimized the delivery of several alphavirus-derived replicon RNA (repRNA) vaccine candidates encoding gH/gL, gH/gL/gp42 or gp350 delivered by a cationic nanocarrier termed LION™. The lead candidate, encoding full-length gH/gL, elicited high titers of neutralizing antibodies that persisted for at least 8 months and a vaccine-specific CD8+ T cell response. Transfer of vaccine-elicited IgG protected humanized mice from EBV-driven tumor formation and death following high-dose viral challenge. These data demonstrate that LION/repRNA-gH/gL is an ideal candidate vaccine for preventing EBV infection and/or related malignancies in humans.